133 CRISPR/Cas9 gene-edited allogeneic CAR-T cells targeting CD33 show high preclinical efficacy against AML without long-term hematopoietic toxicity

Jonathan Terrett, Demetrios Kalaitzidis(Harvard University), Daniel R. Hostetter(University of California, San Francisco), Luis Fernando Gamboa(University of Washington), Robert Chain, Meghna Kuppuraju, Zinkal Padalia, Mohammed G. Ghonime, Brigid McEwan
Regular and Young Investigator Award Abstracts
November 1, 2021
Cited by 0


Related Papers